Poland · Delayed Price · Currency is PLN Read-Gene Company Description
Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland.
The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer.
It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries.
In addition, the company offers genetic tests; and advisory services for genetic counseling and support for oncological genetic counseling centers.
Further, it operates an online platform for genetic tests and genetic-oncological consultations. The company was incorporated in 2005 and is based in Szczecin, Poland.
Read-Gene S.A. operates as a subsidiary of Gen-Pat-Med Sp. z o.o.
| Country | Poland |
| Founded | 2005 |
| Industry | Biotechnology & Medical Research |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Jan Lubinski |
Contact Details
Address: Akacjowa 2 Szczecin Poland | |
| Phone | 48 91 433 4256 |
| Website | read-gene.com |
Stock Details
| Ticker Symbol | RDG |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLRADGN00014 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jan Lubinski | Chief Executive Officer |
| Karolina Ertmanska | Chief Financial Officer |